New J&J Drug Candidates Don't Go It Alone: Companion Dx Are Standard
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's drug business could be a particularly productive partnering site for molecular diagnostics firms over the next several years, statements from one company executive suggest